Abstract
There is no doubt that exposure of humans to high concentrations of metal and metalloid compounds results in the development of specific diseases and in some cases death. Blackfoot disease, hard metal lung disease, itai-itai and Minamata disease are well characterized diseases that are associated with metal exposure. Acute or chronic exposure to metal and metalloid compounds can result in damage to essentially all organ systems. Metal and metalloid ions are hepatotoxic, nephrotoxic and neurotoxic. They can adversely effect the functioning of the endrocrine, hematopoietic, immune, respiratory and reproductive systems. In today’s society, however, exposure to high, cytotoxic concentrations of metal or metalloid compounds is extremely rare. Conversely, everyone is chronically exposed to low non-lethal concentrations of metal and metalloid compounds. While concerns have been raised regarding the potential health risks associated with such exposure, this concept remains controversial. In this chapter, information is presented concerning the potential role(s) that low non-lethal concentrations of metal and metalloid pollutants may have in certain human disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ahlbom A., Norell S., Rodual Y. and Nylander M. (1986). Dentists, dental nurses and brain tumors. B.M.F. 292:662–663.
Ariza ME, Bijur GN, Williams, M.V. 1998. Lead and mercury mutagenesis: role of H2O2, superoxide dismutase and xanthine oxidase. Environ. Mol. Mutagen. 31:352–361
Armstrong R.A., Winsper S.J. and Blair J.A. (1996). Aluminum and Alzheimer’sdisease: review of possible pathogenic mechanisms. Dementia 7: 1–9.
Bates M.N., Smith A.H. and Hopenhayn-Rich C. (1992). Arsenic ingestion and internal cancers: a review. Am. J. Epidemiol. 135:462–476.
Beyersmann D. (1994). Interactions in metal carcinogenicity. Toxicol. Lett. 72:333–338.
Blazka M.E., Harry G.J. and Luster M.I. (1994). Effects of lead acetate on nitrite production by murine brain endothelial cell cultures. Toxicol. Appl. Pharmacol. 126:191–194.
Bondy S.C., Guo-Ross S.X. and Truong A.T. (1998). Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 799: 91–96.
Bush A.I., Pettingell W.H., Multhaup G., Paradis M.D., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L. and Tanzi, R.E. (1994). Rapid induction of Alzheimer’s A beta amyloid formation by zinc. Science 265:1464–1467.
Cohen M.D., Bower D.H. and Costa M. (1996). In Toxicology of Metals. L.W. Cheng (ed.). CRC Lewis Publishers, Boca Raton FL. pp. 253–284.
Connor J.R., Menzies, S.L., St. Martin S.L. and Mufson E.J. (1990). Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27: 595–611.
Conner J.R., Tucker M., Johnson B. and Snyder B. (1993). Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer’s disease. Neurosci. Lett. 159: 88–90.
Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniels S.E., Lees A.J., Jenner P. and Marsden, C.D. (1991). Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953–1975.
Diebel M.A., Ehmann W.D. and Markesberry, W.R. (1996). Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease:possible relation to oxidative stress. J. Neurol. Sci. 143: 137–142.
Gerlach M., Ben-Shachar D., Riederer P. and Youdim M.B.H. (1994). Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63: 793–807.
Gorman A.M., McGowan A., O’Neill C. and Cotter, T. (1996) Oxidative stress and apoptosis in neurodegeneration. J. Neurol. Sci. 139: 45–52.
Gonick H.C., Ding Y., Bondy S.C., Zhenmin N. and Vaziri D. (1997). Lead-induced hypertension. Interplay of nitric oxide and reactive oxygen species. Hypertension 30:1487–1492.
Hartwig A. (1995). Current aspects in metal genotoxicity. BioMetals 8:3–11.
Hassoun P.M., Yu F.S., Zulueta J.J., White A.C., Lanzillo J.J. (1995). Effect of nitric acid and cell redox status on the regulation of endothelial cell xanthine dehydrogenase. Am. J. Physiol. 268:L809–L817.
Hayes R.B. (1997). The carcinogenicity of metals in humans. Cancer Causes Control 8:371–385.
Hertz-Picciotto I. and Croft J. (1993). Review of the relation between blood lead and blood pressure. Epidemiological Rev. 15:352–373.
Hu H., Aro A., Payton M., Korrick S., Sparrow D., Weiss S.T. and Rotnitzky A. (1996). The relationship of bone and blood lead to hypertension. The normative aging study. J. Am. Med. Assoc. 275:1171–1177.
Hua F. and Boffetta P. (1995). Cancer and occupational exposures to inorganic lead compounds: a meta-analysis of published data. Occup. Environ. Med. 52:73–81.
Huang C.-C., Chu N.-S., Lu C.-S., Wang J.-D., Tsai J.-L., Wolters E.C. and Calne D.B. (1989). Chronic manganese intoxication. Arch. Neurol. 46:1104–1106.
Huang P.L. and Fishman M.C. (1996). Genetic analysis of nitric oxide synthase isoforms: targeted mutations in mice. J. Mol. Med. 74:415–421.
IARC (1980). In Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. Vol 23. Some Metals and Metallic Compounds. Lyon: IARC.
IARC (1987). In Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. Supplement 7. Lyon: IARC.
IARC (1990). In Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. Vol 49. Chromium, Nickel and Welding. Lyon: IARC.
IARC (1991). In Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. Vol 52. Chlorinated Drinking Water; Chlorination By-Products; some other Haloginated Compounds; Cobalt and Cobalt Compounds. Lyon: IARC.
IARC (1993). In Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. Vol 58. Beryllium, Cadmium, Mercury and Exposures in the Glass Manufacturing Industry. Lyon: IARC.
Jensen A.A. and Tuchsen F. (1990). Cobalt exposure and cancer risk. Crit. Rev. Toxicol. 20:427–437.
Kasarkis E.J., Tandon L., Lovell M.A., and Ehmann W.D. (1995). Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J. Neurol. Sci. 130: 203–208.
Kawamata T., Tooyama I., Yamada T., Walker D.G. and McGeer P.L. (1993). Lacto-transferrin immunocytochemistry in Alzheimer’s and normal human brain. Am. J. Pathol. 142: 1574–1585.
Kazantzis G. (1981). Role of cobalt, iron, lead, manganese, mercury, platinum, selenium and titnium in carcinogenesis. Environ. Health Prespect. 40:143–161.
Khalil-Manesh F. and Cohen A.H. (1993). Experimental model of lead nephropathy. III. Continuous low-level lead administration. Arch. Environ. Health 48:271–278.
Kim R., Rotnitzky A., Sparrow D., Weiss S.W., Wager C. and Hu H. (1996). A longitudinal study of low-level lead exposure and impairment of renal function. The normative aging study. J. Am. Med. Assoc. 275:1177–1181.
Lockitch G. (1993). Perspectives on lead toxicity. Clin. Biochem. 26:371–381.
Malins D.C., Polissar N.L. and Gunselman S.J. (1996a). Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl. Acad. Sci. USA 93:2557–2563.
Malins D.C., Polissar N.L. and Gunselman S.J. (1996b). Tumor rogression to the metastatic state involves structural modification in DNA markedly different from those associated with primary tumor formation. Proc. Natl. Acad. Sci. USA 93:14047–14052.
Malins D.C., Polissar N.L. and Gunselman S.J. (1997). Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH) and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Proc. Natl. Acad. Sci. USA 94:259–264.
Malins D.C., Polissar N.Y., Schaefer S., Su Y. and Vinson M. (1998). A unified theory of carcinogenesis based on order-disorder transitions in DNA structure as studied in the human ovary and breast. Proc. Natl. Acad. Sci. USA. 95:7637–7642.
Marco-Feced C. In Encyclopaedia of Occupational Health and Safety. 3rd edition. Vol 2. L. Parmeggiani (ed). International Labor Office, Geneva pp. 1281–1282.
Markesbeny W.R. (1997). Oxidative stress hypothesis in Alzheimer’sdisease. Free Radici Biol. Med. 23: 134–147.
Martin J.B. and Gusella J.F. (1986) Huntington’s disease: pathogenesis and management. N. Engl. J. Med. 315: 1267–1276.
McCarthy P.L. and Shklar G. (1980). In Diseases of the Oral Mucosa. Lea and Febiger, Publishers. Philadelphia PA. pp.470–506.
Miyamoto Y., Akaike T., Yoshida M., Goto S., Horie H. and Maeda H. (1996). Potentiation of nitric oxide mediated vasorelaxation by xanthine oxidase inhibitors. Proc. Soc. Exp. Biol. Med. 211:366–373.
Moncada S., Palmer R.M.J. and Higgs E.A. (1991). Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:109–142.
Montgomery, Jr. E.B. (1995). Heavy metals and the etiology of Parkinson’s disease and other movement disorders. Toxicology 97: 3–9.
Multhaup G., Schlicksupp A., Hesse L., Beher D., Ruppert T., Masters C.L. and Beyreuther K. (1996). The amyloid precursor protein of Alzheimer’s disease in the reduction of copper (II) to copper (I). Science 271:1406–1409.
Oberdoester G. and Cherian G. (1988). In Biological Monitoring of Toxic Metals. T.W. Clarkson, L. Friberg, G.F. Nordberg and Z.P.R. Saget (eds). Rochester Ser. Environ. Toxicity. Plenum Press, New York. pp. 283–301.
Payton M., Hu H., Sparrow D. and Weiss S.T. (1994). Low-level lead exposure and renal function in the normative aging study. Am. J. Epidemiol. 140:821–829.
Pines J. (1995). Cyclins, CDKs and cancer. Cancer Biol. 6:63–72.
Pirkle J.L., Schwartz J., Landis J.R. and Harlan W.R. (1985). The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am. J. Epidemiol. 121:246–258.
Qian Z.M. and Wang Q. (1998). Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res. Rev. 27: 257–267.
Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G.P., Jellinger K. and Youdim, M.B.H. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem. 52:515–520.
Rybicki B.A., Johnson C.C., Uman J. and Gorell J.M. (1993). Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov. Disord. 8: 87–92.
Schwartz J. (1995). Lead, blood pressure and cardiovascular disease in men. Arch. Environ. Health 50:31–37.
Smith M.A., Perry G., Richey P.L., Sayre, L.M., Anderson, V.E., Beal M.F. and Kowall N. (1996). Oxidative damage in Alzheimer’s. Science, 382:120–121.
Staessen J.A., Lauwerys R.R., Buchet J.P., Bulpitt C.J., Rondia D., Vanrenterghem Y. and Amery A. The Cadmibel Study Group. (1992). Impairment of renal function with increasing blood lead concentrations in the general population. New. Engl. J. Med. 327:151–156.
Toyokuni S. (1996). Iron-induced carcinogenesis: the role of redox regulation. Free Radical Biol. Med. 20:553–566.
Waalkes M.P. (1992). Toxicological principles of metal carcinogenesis with special emphasis on cadmium. Crit. Rev. Toxicol. 22:175–201.
Waalkes M.P. and Rhem S. (1994). Cadmium and prostate cancer. J. Toxicol. Environ. Health 43:251–269.
Weiss S.T., Munoz A., Stein A., Sparrow D. and Speizer F.E. (1986). The relationship of blood lead to blood pressure in a longitudinal study of working men. Am. J. Epidemiol. 123:800–808.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ariza, M.E., Bijur, G.N., Williams, M.V. (1999). Effects of Environmental Metal and Metalloid Pollutants on Human Health. In: Environmental Metal Pollutants, Reactive Oxygen Intermediaries and Genotoxicity. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5153-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5153-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7346-9
Online ISBN: 978-1-4615-5153-9
eBook Packages: Springer Book Archive